US biopharmaceutical companies have shown some progress in product development during the third quarter and first nine months of 1996. However, the majority of them continue to make a loss.
At Allergan Ligand Retinoid Therapeutics, R&D expenses were $9.4 million in the 1996 third quarter, and $22.1 million in the first nine months of the year. R&D was primarily performed under contract by the parent companies Allergan and Ligand.
President of Arris Pharmaceutical, John Walker, said that the firm's collaborative partners remain the source of support for the majority of his company's research efforts and the entire $5.2 million in reported revenues for the third quarter of 1996.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze